• Gen AI investments: The company has deployed an annualized $6 million into generative AI capabilities and go-to-market strategies, creating a 1.5% margin drag that is expected to pay back over the next three to four quarters.
• Revenue mix breakdown: Enterprise commercial constitutes over 70% of total revenue, enterprise medical accounts for 25% to 26%, and clinical and consulting forms the remaining 4%, with commercial expected to stay above 65% over the longer term.
• Biotech segment recovery: After dropping below 2% of revenue, biotech contribution has recovered toward 3% on renewed sector funding and two new client contracts exceeding $5 million each.
• Deal size trends: Shifting from experimentation to full-scale Gen AI deployment has driven deal sizes higher—including multiple deals above $1 million and $10 million—while top 10 global pharma clients represent 51% of total revenue.
• FY27 growth targets: Management is targeting growth north of 20% in FY27, with bottom-line growth projected to outpace top-line growth as margin expansion becomes more pronounced in the second half.